DEVELOPMENT AND CHARACTERIZATION OF TACROLIMUS TABLET FORMULATIONS FOR SUBLINGUAL ADMINISTRATION
Objective: The study aimed to prepare and characterize inclusion complexes of tacrolimus with β-cyclodextrin to improve its solubility and to formulate them into sublingual fast disintegrating tablets with a view to bypass the first pass metabolism.
Methods: Tacrolimus: β- cyclodextrin inclusion complexes (1:1 and 1:2 molar proportions) were prepared using the kneading method. Their characterization was accomplished by determining the drug content, solubility, Attenuated Total Reflection-Infrared Spectroscopy (ATR-IR), Scanning Electron Microscopy (SEM), Differential Scanning Calorimetry (DSC), and powder X-Ray Diffraction analysis (pXRD). These were then formulated to fast disintegrating tablets and evaluated for precompression as well as post compressional characteristics.
Results: SEM analysis showed the inclusion complexes as rough, non-porous, irregular surfaced aggregate particles. DSC and pXRD analyses confirm the crystallinity change and partial conversion to the amorphous form of the drug in the inclusion complexes. From the solubility studies, it was observed that both the inclusion complexes of 1:2 molar ratio (14.82±0.889 µg/ml) and 1:1 molar ratio (12.72±0.1004 µg/ml) improved the aqueous solubility to greater extents in comparison to that of the pure drug (3.05±0.121 µg/ml). All the tablet formulations showed good precompression and mechanical properties. The inclusion complex loaded tablets exhibited a superior drug release pattern when compared to tablets prepared with tacrolimus alone. The optimized formulation (TT3) showed an in vitro disintegration time of 34.33 s and a per cent drug release of 97.87.
Conclusion: The inclusion complex formulation combined with the sublingual route of administration can be expected to result in an improved bioavailability of tacrolimus by increasing its solubility and bypassing first pass metabolism.
Park YJ, Ryu DS, Li DX, Quan QZ, Oh DH, Kim JO, et al. Physicochemical characterization of tacrolimus-loaded solid dispersion with sodium carboxylmethyl cellulose and sodium lauryl sulfate. Arch Pharm Res 2009;32:893–8.
Tamura S, Ohike A, Ibuki R, Amidon GL, Yamashita S. Tacrolimus is a class II low-solubility high-permeability drug: The effect of P-glycoprotein efflux on regional permeability of tacrolimus in rats. J Pharm Sci 2002;91:719–29.
Joint formulary committee. British National Formulary 56. BMJ Group. 2008; 483.
Van Duijnhoven E, Christiaans M, Undre N, Stevenson P, Van Hooff J. The effect of breakfast on the oral bioavailability of tacrolimus in diabetic and nondiabetic patients before transplantation. Transplant Proc 1998;30:1268–70.
Patel P, Patel H, Mehta T, Panchal S. Formulation strategies for drug delivery of tacrolimus: An overview. Int J Pharm Investig 2012;2:169-75.
Srinarong P, Pham BT, Holen M, Van Der Plas A, Schellekens RCA, Hinrichs WLJ, et al. Preparation and physicochemical evaluation of a new tacrolimus tablet formulation for sublingual administration. Drug Dev Ind Pharm 2012;38:490–500.
Zidan AS. Taste-masked tacrolimus-phospholipid nanodispersions: dissolution enhancement, taste masking and reduced gastric complications. Pharm Dev Technol 2017;22:173–83.
Chung Y, Cho H. Preparation of highly water soluble tacrolimus derivatives: poly(ethylene glycol) esters as potential prodrugs. Arch Pharm Res 2004;27:878–83.
Yamashita K, Nakate T, Okimoto K, Ohike A, Tokunaga Y, Ibuki R, et al. Establishment of new preparation method for solid dispersion formulation of tacrolimus. Int J Pharm 2003;267:79–91.
Yoshida T, Kurimoto I, Yoshihara K, Umejima H, Ito N, Watanabe S, et al. Aminoalkyl methacrylate copolymers for improving the solubility of tacrolimus. I: Evaluation of solid dispersion formulations. Int J Pharm 2012;428:18–24. http://dx.doi.org/10.1016/j.ijpharm.2012.02.041
Kovvasu SP, Kunamaneni P, Kunderu RS. Cyclodextrins and their application in enhancing the solubility, dissolution rate and bioavailability. Innoriginal Int J Sci 2018;5:25–34.
Al Sagheer T, Enderby CY. Determining the conversion ratios for oral versus sublingual administration of tacrolimus in solid organ transplant recipients. Clin Transplant 2019;33:e13727.
Solari S, Cancino A, Wolff R, Norero B, Vargas JI, Barrera F et al. Sublingual tacrolimus administration provides similar drug exposure to per-oral route employing lower doses in liver transplantation : a pilot study. Aliment Pharmacol Ther 2017;45:1225-31.
Watkins KD, Boettger RF, Hanger KM, Leard LE, Golden JA, Hoopes CW, et al. Use of sublingual tacrolimus in lung transplant recipients. J Heart Lung Transplant 2012;31:127–32. http://dx.doi.org/10.1016/j.healun.2011.10.015
Nasiri-Toosi Z, Dashti-Khavidaki S, Nasiri-Toosi M, Khalili H, Jafarian A, Irajian H, et al. Clinical pharmacokinetics of oral versus sublingual administration of tacrolimus in adult liver transplant recipients. Exp Clin Transplant 2012;10:586–91.
Arima H, Yunomae K, Miyake K, Irie T, Hirayama F, Uekama K. Comparative studies of the enhancing effects of cyclodextrins on the solubility and oral bioavailability of tacrolimus in rats. J Pharm Sci 2001;90:690–701.
Tacrolimus Revision bulletin. The United States Pharmacopoeia. The United States Pharmacopoeial Convention. 2013:3–5.
Joe JH, Lee WM, Park YJ, Joe KH, Oh DH, Seo YG, et al. Effect of the solid-dispersion method on the solubility and crystalline property of tacrolimus. Int J Pharm 2010;395:161–6.
Dattatraya SM, Aher PS, Kothawade PD, Maru AD. Formulation and in vitro evaluation of fast dissolving tablet of verapamil hydrochloride. Int J Pharm Pharm Sci 2018;10:93-9.
Purkayastha HD, Nath B. Formulation and evaluation of oral fast disintegrating tablet of ibuprofen using two super disintegrants. Int J Curr Pharm Res 2017;9:92-5.
Choudhury P, Deb P, Dash S. Formulation and statistical optimization of bilayer sublingual tablets of levocetirizine hydrochloride and ambroxol hydrochloride. Asian J Pharm Clin Res 2016;9:228-34.
Lachman L, Lieberman HA Kanig JL. The theory and practice of industrial pharmacy. Lea & Febiger. 1987;296–301.
Tashan E, Karakucuk A, Celebi N. Development of nanocrystal ziprasidone orally disintegrating tablets: optimization by using design of experiment and in vitro evaluation. AAPS PharmSciTech 2020;21:115.
Prajapati ST, Patel PB, Patel CN. Formulation and evaluation of sublingual tablets containing Sumatriptan succinate. Int J Pharm Investig. 2012;2:162-8.
Rawas-Qalaji MM, Simons FE, Simons KJ. Fast-disintegrating sublingual epinephrine tablets: effect of tablet dimensions on tablet characteristics. Drug Dev Ind Pharm. 2007;33:523–30.
Jaya S, Amala V. Formulation and in vitro evaluation of oral disintegrating tablets of amlodipine besylate. Int J App Pharm 2019;11:49-54.
Ponnammal P, Kanaujia P, Yani Y, Ng WK, Tan RBH. Orally disintegrating tablets containing melt extruded amorphous solid dispersion of tacrolimus for dissolution enhancement. Pharmaceutics. 2018;10:35.
Kassem AA, Labib GS. Flash dissolving sublingual almotriptan malate lyotabs for management of migraine. Int J Pharm Pharm Sci 2017;9:125-131.
Indian Pharmacopoeia. Volume II. Government of India, Ministry of health and family welfare. The Indian Pharmacopoeia Commission, Ghaziabad. 2014.
Rojas J, Guisao S, Ruge V. Functional assessment of four types of disintegrants and their effect on the spironolactone release properties. AAPS PharmSciTech. 2012;13:1054–62.
Tacrolimus Capsules Revision Bulletin. The United States Pharmacopoeia. The United States Pharmacopoeial Convention. 2018:1–7.
How to Cite
Copyright (c) 2021 JISHA MOHANAN, SEENIVASAN PALANICHAMY, ARUL KUTTALINGAM, DAMODHARAN NARAYANASAMY
This work is licensed under a Creative Commons Attribution 4.0 International License.